Strive Asset Management has raised $750 million to pursue the strategy while Ramaswamy runs to be Ohio’s governor.

Biotech goes back to the future to target Parkinson's disease 23andMe deal details: What's not included, and surprise second ...

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...

Discover the key biotech trends moving the industry forward in Europe at a time when there lies uncertainty in global ...

Samsung Biologics, the biopharmaceutical arm of Samsung Group, said on May 26 it had secured two contract manufacturing deals ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...

Eikon Therapeutics, a Bay Area biotech startup with $1.1 billion in funding, is laying off dozens of employees and pointing ...

ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast ...

A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Facebook parent company Meta Platforms asked a federal judge on Thursday to throw out the U.S. Federal Trade Commission's ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...